LBD5 Antibody
Description
Potential Terminology Clarification
The term "LBD5" does not correspond to established antibody nomenclature or known biological targets. Possible interpretations include:
Key Antibodies in Lewy Body Disease Research
While "LBD5" remains unidentified, notable antibodies targeting Lewy body pathology include:
α-Synuclein Truncation-Specific Antibodies
Developed to detect disease-specific α-synuclein modifications in Lewy bodies :
| Antibody | Target Epitope | Pathology Specificity | Key Applications |
|---|---|---|---|
| 94-3A10 | αSyn x-129 | Alzheimer’s/amygdala LBD | Distinguishes AD/ALB vs. LBD |
| 2G5 | αSyn 1–103 | MSA, LBD | Detects oligodendroglial inclusions |
| 5C1 | αSyn x-125 | LBD aggregates (ethanol-fixed tissue) | Biochemical validation of insoluble αSyn |
Therapeutic Antibodies
Research Gaps and Recommendations
-
Validation of "LBD5": No publications or patents reference this designation. Cross-referencing genomic or proteomic databases (e.g., UniProt, ClinicalTrials.gov) yields no matches.
-
Alternative Targets: Prioritize antibodies against validated Lewy body biomarkers (e.g., α-synuclein truncations) or explore biparatopic antibodies for enhanced therapeutic efficacy.
-
Commercial Antibody Screening: Use platforms like Antibody Society’s product database to identify antibodies with specificity aligned to experimental needs.
